Moderna (MRNA) said Friday it has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for mRESVIA, its respiratory syncytial virus vaccine for adults 60 and over.

RSV is a highly contagious seasonal virus that causes lower respiratory tract infections and pneumonia, the company said.

The approval is based on the phase 3 ConquerRSV trial, which included around 37,000 adults aged 60 and older across 22 countries, the company said, adding that the trial found no serious safety concerns.

MRNA shares were 0.6% higher in recent trading.

Price: 31.28, Change: +0.19, Percent Change: +0.61